Key baseline characteristics for the ITT population
| . | All participants . | ≥75 years old . | ||
|---|---|---|---|---|
| Characteristic . | ≥75 years old . | <75 years old . | Sitagliptin . | Placebo . |
| (n = 2,004) . | (n = 12,347) . | (n = 970) . | (n = 1,034) . | |
| Male sex | 1,356 (67.7) | 8,847 (71.7) | 682 (70.3) | 674 (65.2) |
| Age (years) | 78.3 ± 3.1 | 63.4 ± 6.4 | 78.3 ± 3.0 | 78.4 ± 3.2 |
| BMI (kg/m2)* | 28.9 ± 4.8 | 30.3 ± 5.7 | 29.0 ± 4.9 | 28.9 ± 4.8 |
| Systolic blood pressure (mmHg)* | 137 ± 18 | 134 ± 17 | 137 ± 18 | 137 ± 18 |
| Diastolic blood pressure (mmHg)* | 74 ± 11 | 78 ± 10 | 74 ± 11 | 74 ± 11 |
| HbA1c (%)* | 7.18 ± 0.46 | 7.24 ± 0.48 | 7.19 ± 0.46 | 7.17 ± 0.46 |
| HbA1c (mmol/mol)* | 55.0 ± 5.1 | 55.7 ± 5.2 | 55.1 ± 5.1 | 54.8 ± 5.0 |
| eGFR (mL/min/1.73 m2)* | 65.5 ± 19.2 | 76.3 ± 21.0 | 65.3 ± 19.0 | 65.7 ± 19.3 |
| ≥90 | 205 (10.3) | 3,026 (24.8) | 95 (9.9) | 110 (10.8) |
| 60–89 | 963 (48.6) | 6,761 (55.3) | 474 (49.4) | 489 (47.8) |
| 30–59 | 814 (41.0) | 2,437 (19.9) | 390 (40.6) | 424 (41.4) |
| <30 | 1 (0.1) | 2 (<0.1) | 1 (<1.0) | 0 |
| LDL cholesterol (mmol/L)* | 2.3 ± 2.6 | 2.4 ± 1.2 | 2.4 ± 3.7 | 2.2 ± 0.9 |
| Median duration of diabetes, years (IQR)* | 12 (7, 21) | 9 (5, 15) | 13 (7, 21) | 12 (7, 21) |
| Prior heart failure* | 422 (21.1) | 1,970 (16.0) | 190 (19.6) | 232 (22.4) |
| Medication use | ||||
| Metformin* | 1,449 (72.3) | 10,265 (83.1) | 711 (73.3) | 738 (71.4) |
| Sulfonylurea | 946 (47.2) | 5,569 (45.1) | 442 (45.6) | 504 (48.7) |
| Insulin | 501 (25.0) | 2,844 (23.0) | 255 (35.6) | 246 (33.8) |
| Median daily dose, units (IQR) | 51.0 (34.0, 80.0) | 44.0 (28.0, 67.5) | 44.0 (28.0, 72.0) | 42.0 (28.5, 64.0) |
| Monotherapy for type 2 diabetes* | 1,066 (53.2) | 5,755 (46.6) | 514 (53.0) | 552 (53.4) |
| Dual combination therapy for type 2 diabetes* | 913 (45.6) | 6,477 (52.5) | 446 (46.0) | 467 (45.2) |
| Aspirin* | 1,473 (73.5) | 9,829 (79.6) | 702 (72.4) | 771 (74.6) |
| Any antiplatelet* | 1,591 (79.4) | 10,443 (84.6) | 771 (79.5) | 820 (79.3) |
| Statin | 1,582 (78.9) | 9,998 (81.0) | 761 (78.5) | 821 (79.4) |
| Any lipid lowering | 1,641 (81.9) | 10,340 (83.7) | 797 (82.2) | 844 (81.6) |
| . | All participants . | ≥75 years old . | ||
|---|---|---|---|---|
| Characteristic . | ≥75 years old . | <75 years old . | Sitagliptin . | Placebo . |
| (n = 2,004) . | (n = 12,347) . | (n = 970) . | (n = 1,034) . | |
| Male sex | 1,356 (67.7) | 8,847 (71.7) | 682 (70.3) | 674 (65.2) |
| Age (years) | 78.3 ± 3.1 | 63.4 ± 6.4 | 78.3 ± 3.0 | 78.4 ± 3.2 |
| BMI (kg/m2)* | 28.9 ± 4.8 | 30.3 ± 5.7 | 29.0 ± 4.9 | 28.9 ± 4.8 |
| Systolic blood pressure (mmHg)* | 137 ± 18 | 134 ± 17 | 137 ± 18 | 137 ± 18 |
| Diastolic blood pressure (mmHg)* | 74 ± 11 | 78 ± 10 | 74 ± 11 | 74 ± 11 |
| HbA1c (%)* | 7.18 ± 0.46 | 7.24 ± 0.48 | 7.19 ± 0.46 | 7.17 ± 0.46 |
| HbA1c (mmol/mol)* | 55.0 ± 5.1 | 55.7 ± 5.2 | 55.1 ± 5.1 | 54.8 ± 5.0 |
| eGFR (mL/min/1.73 m2)* | 65.5 ± 19.2 | 76.3 ± 21.0 | 65.3 ± 19.0 | 65.7 ± 19.3 |
| ≥90 | 205 (10.3) | 3,026 (24.8) | 95 (9.9) | 110 (10.8) |
| 60–89 | 963 (48.6) | 6,761 (55.3) | 474 (49.4) | 489 (47.8) |
| 30–59 | 814 (41.0) | 2,437 (19.9) | 390 (40.6) | 424 (41.4) |
| <30 | 1 (0.1) | 2 (<0.1) | 1 (<1.0) | 0 |
| LDL cholesterol (mmol/L)* | 2.3 ± 2.6 | 2.4 ± 1.2 | 2.4 ± 3.7 | 2.2 ± 0.9 |
| Median duration of diabetes, years (IQR)* | 12 (7, 21) | 9 (5, 15) | 13 (7, 21) | 12 (7, 21) |
| Prior heart failure* | 422 (21.1) | 1,970 (16.0) | 190 (19.6) | 232 (22.4) |
| Medication use | ||||
| Metformin* | 1,449 (72.3) | 10,265 (83.1) | 711 (73.3) | 738 (71.4) |
| Sulfonylurea | 946 (47.2) | 5,569 (45.1) | 442 (45.6) | 504 (48.7) |
| Insulin | 501 (25.0) | 2,844 (23.0) | 255 (35.6) | 246 (33.8) |
| Median daily dose, units (IQR) | 51.0 (34.0, 80.0) | 44.0 (28.0, 67.5) | 44.0 (28.0, 72.0) | 42.0 (28.5, 64.0) |
| Monotherapy for type 2 diabetes* | 1,066 (53.2) | 5,755 (46.6) | 514 (53.0) | 552 (53.4) |
| Dual combination therapy for type 2 diabetes* | 913 (45.6) | 6,477 (52.5) | 446 (46.0) | 467 (45.2) |
| Aspirin* | 1,473 (73.5) | 9,829 (79.6) | 702 (72.4) | 771 (74.6) |
| Any antiplatelet* | 1,591 (79.4) | 10,443 (84.6) | 771 (79.5) | 820 (79.3) |
| Statin | 1,582 (78.9) | 9,998 (81.0) | 761 (78.5) | 821 (79.4) |
| Any lipid lowering | 1,641 (81.9) | 10,340 (83.7) | 797 (82.2) | 844 (81.6) |
Data are n (%) or mean ± SD, except where indicated. P values comparing sitagliptin and placebo groups were not calculated. See Supplementary Table 2 for full list of baseline characteristics.
*P values <0.0001 comparing older to younger cohorts.